Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC148 plus platinum chemotherapy vs tislelizumab plus platinum chemotherapy in first-line advanced squamous NSCLC
CTR20260535Phase 3Active
- Sponsor
- RemeGen
- Start
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RC148 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by RemeGen. Primary endpoint: Progression-free survival (PFS) by BIRC per RECIST v1.1. Started Apr 2026; status: active.
02
Drugs
RC148
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20260535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260535.